Maintenance Phase Podcast Summary: Ozempic Episode (Released October 10, 2023)

Hosts: Aubrey Gordon & Michael Hobbes

Introduction

In this episode of Maintenance Phase, hosts Aubrey Gordon and Michael Hobbes delve deep into the controversy surrounding Ozempic and Wegovy, medications containing the active ingredient semaglutide. They aim to debunk the myths, scrutinize the scientific claims, and address the societal implications of these weight loss drugs.

Overview of Ozempic and Semaglutide

Aubrey Gordon [16:04]: "Semaglutide mimics the GLP1 hormone released after eating, signaling fullness and regulating insulin production."

Ozempic and Wegovy are both injectable medications developed by Novo Nordisk. While Ozempic is prescribed for managing type 2 diabetes, Wegovy is marketed for weight loss, utilizing a higher dosage of semaglutide. Semaglutide, a GLP1 agonist, plays a crucial role in regulating hunger and satiety signals in the body.

Origins and Development

Aubrey Gordon [08:33]: "Dr. Daniel Drucker discovered GLP1 in 1984, leading to the development of semaglutide after studying the Gila monster’s unique appetite-regulating genes."

The journey of semaglutide began in 1984 with Dr. Daniel Drucker at the University of Toronto, who identified the GLP1 hormone. Inspired by the Gila monster's ability to regulate its appetite and metabolism, researchers synthesized semaglutide, aiming to create a longer-lasting version of GLP1 for therapeutic use.

Clinical Trials and Effectiveness

Michael Hobbs [24:59]: "Approximately one-third of participants in a two-year trial lost more than 20% of their body weight, comparable to bariatric surgery."

Clinical trials, particularly the STEP trials, have demonstrated remarkable weight loss results:

• 80% of participants lost at least 5% of their body weight.
• 50% shed between 10-15%.
• 33% achieved over 20% weight loss, matching outcomes typically seen with bariatric surgery.

Additionally, these medications have shown significant health benefits, including improved blood pressure, cholesterol levels, and A1C for diabetic patients. Longer trials indicate reductions in heart attacks and strokes, positioning semaglutide as a potentially life-saving drug beyond weight loss.

Side Effects and Safety Concerns

Michael Hobbs [25:31]: "Gastrointestinal symptoms like nausea and vomiting are almost universal, occurring in up to 93% of users."

Despite their effectiveness, semaglutide comes with a range of side effects:

• Common: Nausea, constipation, diarrhea, and vomiting, affecting up to 93% of users.
• Serious: Concerns about pancreatitis, thyroid cancer (based on rodent studies), gallbladder disease, acute kidney injury, and rare cases of suicidal ideation and ileus (a potentially fatal bowel obstruction).

The FDA has updated semaglutide’s label to include ileus after 33 cases and two deaths, highlighting ongoing safety evaluations.

Real-World Effectiveness vs. Clinical Trials

Michael Hobbs [38:00]: "Real-world studies show that weight loss results are roughly half of what clinical trials report."

In contrast to controlled clinical settings, real-world usage of semaglutide shows:

• An average weight loss of 7.5%, significantly lower than the 15% reported in trials.
• Dropout rates in real-world settings can reach up to 70%, compared to a mere 6% in some trials.

Factors contributing to this discrepancy include the intensive behavioral therapy provided during trials and higher adherence rates due to the structured environment of clinical studies.

Discourse and Stigma Around Weight Loss and Fatness

Aubrey Gordon [33:11]: "The stigma surrounding weight loss drugs like Ozempic reinforces fatphobia and dehumanizes fat individuals."

The hosts critically examine the societal narratives surrounding Ozempic:

• Stigmatization: Users are often labeled as taking the "easy way out," perpetuating harmful stereotypes about fat individuals being lazy or unattractive.
• Media Representation: Headlines such as "Ozempic settles the obesity debate" and campaigns like Novo Nordisk's "It's Bigger Than Me" aim to reduce personal blame but inadvertently fuel anti-fat bias.
• Economic Barriers: The high cost of Wegovy ($1,300/month) and Ozempic ($900/month) limits access, primarily benefiting those with disposable income and exacerbating inequalities.
• Social Reinforcement: Weight loss is tied to perceived virtue, leading to increased stigma for those who remain overweight and further isolation for fat individuals.

Michael Hobbs [33:33]: "Doctors prescribing Ozempic for unrelated issues, like migraines, exemplify systemic bias and lack of individualized care."

Marketing Practices of Novo Nordisk

Aubrey Gordon [48:12]: "Novo Nordisk's 'It's Bigger Than Me' campaign leverages influential Black figures to reshape the narrative around obesity."

Novo Nordisk has employed strategic marketing campaigns to position semaglutide as a medical solution rather than a lifestyle choice:

• Campaigns: "It's Bigger Than Me" uses spokespeople like Queen Latifah and Yvette Nicole Brown to promote the drug, emphasizing that obesity is a disease requiring medical intervention.
• Media Integration: Branded segments on TV shows aim to normalize the use of Ozempic and Wegovy, though often practiced superficially without addressing deeper societal issues.
• Critique: The hosts argue that these marketing efforts mask the underlying fatphobia and shift the conversation without providing meaningful support for affected individuals.

Conclusions and Final Thoughts

Aubrey Gordon [56:04]: "This is another round of scapegoating fat people, masking deeper societal issues with medical solutions."

Aubrey and Michael conclude that while semaglutide presents promising clinical benefits, the surrounding discourse and systemic barriers undermine its potential to address obesity comprehensively. They emphasize the need to:

• Center Affected Voices: Prioritize the experiences and needs of fat and diabetic individuals in discussions about weight loss medications.
• Address Stigma: Actively work to dismantle the pervasive fatphobia reinforced by media and societal narratives.
• Ensure Equitable Access: Advocate for broader insurance coverage and affordability to prevent further entrenchment of health disparities.

The episode underscores the complexity of using medical interventions to address societal and personal issues related to weight, highlighting the importance of a compassionate and equitable approach.

Notable Quotes with Timestamps

• Aubrey Gordon [02:33]: "We're spending basically this entire episode talking about the narratives around Ozempic and Wegovy."
• Michael Hobbs [07:28]: "Semaglutide works by triggering your satiety hormone, making you feel full longer and helping you eat less overall."
• Michael Hobbs [25:45]: "Even if you take the weight loss stuff off the table, the health benefits are comparable to statins, which are a big deal."
• Aubrey Gordon [43:09]: "Ask a fat person. Has anybody tried to teach you how to cook? Has anybody offered you a gym membership?"
• Michael Hobbs [45:25]: "Take the fucking stairs. It's like, well, you might look thin, but you're really a fat person."
• Aubrey Gordon [55:52]: "Fat people, like, taking that message. That's horrible."

This detailed analysis by Aubrey Gordon and Michael Hobbes offers a critical perspective on the rise of Ozempic and Wegovy, highlighting the intersection of pharmaceutical advancements with societal attitudes towards weight and health.